Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.
作者： Nicole Mittmann , Paul I Oh , Scott E Walker , William R Bartle
DOI: 10.2165/00019053-200422100-00005
关键词:
摘要: Background: The bioavailability of warfarin is an important factor affecting the achievement therapeutic anticoagulation. It uncertain whether less expensive generic preparations would compromise prevention thromboembolism or increase bleeding risk in patients with atrial fibrillation.
springer.com
sci-hub.se 参考文章(19)
H. D. White, Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary The Lancet. ,vol. 343, pp. 687- 691 ,(1994)
A. Laupacis, D. Feeny, P. X. Tugwell, A. S. Detsky, Tentative guidelines for using clinical and economic evaluations revisited Canadian Medical Association Journal. ,vol. 148, pp. 927- 929 ,(1993)
A. Laupacis, D. Feeny, P. X. Tugwell, A. S. Detsky, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Canadian Medical Association Journal. ,vol. 146, pp. 473- 481 ,(1992)
Jack Hirsh, James E. Dalen, Gordon Guyatt, The Sixth (2000) ACCP Guidelines for Antithrombotic Therapy for Prevention and Treatment of Thrombosis Chest. ,vol. 119, pp. 1- ,(2001) , 10.1378/CHEST.119.1_SUPPL.1S
Jeanne M. DeCara, Sheila Croze, Rodney H. Falk, Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card? Chest. ,vol. 113, pp. 261- 263 ,(1998) , 10.1378/CHEST.113.2.261
Richard H. White, Hong Zhou, Patrick Romano, Dennis Mungall, Changes in plasma warfarin levels and variations in steady-state prothrombin times. Clinical Pharmacology & Therapeutics. ,vol. 58, pp. 588- 593 ,(1995) , 10.1016/0009-9236(95)90179-5
B S P Hellemons, M Langenberg, J Lodder, F Vermeer, H J A Schouten, T. Lemmens, J W van Ree, J A Knottnerus, Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. ,vol. 319, pp. 958- 964 ,(1999) , 10.1136/BMJ.319.7215.958
Palle Petersen, John Godtfredsen, Gudrun Boysen, EllenD Andersen, Bjørn Andersen, Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. The Lancet. ,vol. 333, pp. 175- 179 ,(1989) , 10.1016/S0140-6736(89)91200-2
Sheila Richton-Hewett, Medical and Economic Consequences of a Blinded Oral Anticoagulant Brand Change at a Municipal Hospital Archives of Internal Medicine. ,vol. 148, pp. 806- 808 ,(1988) , 10.1001/ARCHINTE.1988.00380040046010
Annette Lemche Gulløv, Birgitte Gade Koefoed, Palle Petersen, Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation The AFASAK 2 Study JAMA Internal Medicine. ,vol. 159, pp. 1322- 1328 ,(1999) , 10.1001/ARCHINTE.159.12.1322